Farmakologin i början av nytt millennium: Större sortiment och individuell dosering av läkemedel på väg

Lakartidningen

Volumn 98, Issue 6, 2001, Pages 534-539

  Fredholm, Bertil B ^a,b   Sjöqvist, Folke ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b IUPHAR ^*

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PHARMACOLOGY; DRUG ADMINISTRATION; DRUG COST; DRUG DOSAGE FORM; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; HEALTH CARE QUALITY; HUMAN; PHARMACOGENETICS; PRESCRIPTION; STANDARD;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG INFORMATION SERVICES; DRUG UTILIZATION; HUMANS; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; PRESCRIPTIONS, DRUG; QUALITY INDICATORS, HEALTH CARE;

EID: 17044449117     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rosén A, Beerman B. Rating innovative therapeutic benefits of medicines prescribed in Sweden 1987-97. International Journal of Pharmaceutical Medicine 1999; 13: 123-7.
2. Norinder A, Nordling S, Häggström L. Priset per tablett dålig indikator i ett samhällsekonomiskt perspektiv. Läkartidningen 2000; 97: 1693-700.
3. Drews J. Drug discovery: A historical perspective. Science 2000; 287: 1960-4.
4. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857-65.
5. Schreiber SL. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000; 287: 1964-8.
6. Risch NJ. Searching for genetic determinants in the new millenium. Nature 2000; 405: 847-56.
7. Knowles MR, Olivier K, Noone P, Boucher RC. Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis. Am J Respir Crit Care Med 1995; 151: S65-9.
8. Fredholm BB. Vägen från genomstruktur till bot av sjukdom är lång och krokig. Forskare med molekylär inriktning och forskare som kan fysiologi bör samarbeta. Läkartidningen 2000; 97: 2046-8.
9. Knoppers BM, Hirtle M, Glass KC. Commercialization of genetic research and public policy. Science 2000; 296: 2277-8.
10. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.
11. Johansson J, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 190: 11825-9.
12. Sjöqvist F. Drug safety in relation to efficacy: the view of a clinical pharmacologist. Pharmacol Toxicol 2000; 86 suppl 1: 30-2.
13. Bergman U, Wiholm BE. Drug-related problems causing admission to a medical clinic. Eur J Clin Pharmacol 1981; 520: 193-200.
14. Mjörndal T, Danell Bohman M, Bäckström M, Dahlqvist R, Hägg S, Wahlin A et al. Adverse drug reactions as a cause for admission to a clinic of internal medicine. Abstract, Third congress of the European association for clinical pharmacology and therapeutics, Jerusalem, October 1999. Br J Clin Pharmacol 1999; suppl: 3-8.
15. Göttler M. ADR-related hospital admission of the elderly- a literature-based meta-analysis. Abstracts, seventh annual meeting, European society of pharmacovigilance, Ankara, September 23-24, 1999.
16. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies [comments]. JAMA 1998; 279: 1200-5.
17. Weatherall M. In search of a Cure. Oxford: Oxford University Press, 1990.
18. Fredholm BB. Vi behöver också fler som kan informera om läkemedel. Läkartidningen 1998; 95: 3278-80.
19. Reich MR. The global drug gap. Science 2000; 287: 1979-81.
20. Sjöqvist F. Clinical pharmacology, past, present and future. Eur J Clin Pharmacol 1999; 55: 553-7.